Ustekinumab – Treatment for Plaque Psoriasis

Discovered and developed by Centocor, ustekinumab (CNTO 1275) is an investigational MAb with a novel dual mechanism of action. Its initial indication is for the treatment of moderate to severe plaque psoriasis.